These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27111559)

  • 1. Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes.
    Fekih O; Triki H; Triki S; Neffati F; Chouchane S; Guediche MN; Najjar MF
    Pediatr Diabetes; 2017 May; 18(3):230-236. PubMed ID: 27111559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin, RANKL, ADMA, and Fetuin-A serum levels in children with type I diabetes mellitus.
    Chrysis D; Efthymiadou A; Mermigka A; Kritikou D; Spiliotis BE
    Pediatr Diabetes; 2017 Jun; 18(4):277-282. PubMed ID: 27028343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteoprotegerin levels, endothelial function and carotid intima-media thickness in type 2 diabetic patients.
    Gunes M; Temizkan S; Apaydin T; Ilgin C; Haklar G; Gogas Yavuz D
    J Diabetes Complications; 2021 Dec; 35(12):108073. PubMed ID: 34635402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.
    Demir P; Erdenen F; Aral H; Emre T; Kose S; Altunoglu E; Dolgun A; Inal BB; Turkmen A
    J Clin Lab Anal; 2016 Nov; 30(6):811-817. PubMed ID: 26991325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased Circulating Osteoprotegerin Levels in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis Based on Observational Studies.
    Duan CC; Ma C; Tang HQ
    Immunol Invest; 2021 Feb; 50(2-3):101-112. PubMed ID: 31920120
    [No Abstract]   [Full Text] [Related]  

  • 6. Carotid intima media thickness and associations with serum osteoprotegerin and s-RANKL in children and adolescents with type 1 diabetes mellitus with increased risk for endothelial dysfunction.
    Karavanaki K; Tsouvalas E; Vakaki M; Soldatou A; Tsentidis C; Kaparos G; Augoulea A; Alexandrou A; Lambrinoudaki Ι
    J Pediatr Endocrinol Metab; 2018 Nov; 31(11):1169-1177. PubMed ID: 30352039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
    Karalazou P; Ntelios D; Chatzopoulou F; Fragou A; Taousani M; Mouzaki K; Galli-Tsinopoulou A; Kouidou S; Tzimagiorgis G
    Ital J Pediatr; 2019 Dec; 45(1):161. PubMed ID: 31823791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus.
    Tavintharan S; Pek LT; Liu JJ; Ng XW; Yeoh LY; Su Chi L; Chee Fang S
    Diab Vasc Dis Res; 2014 Sep; 11(5):359-62. PubMed ID: 25005034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status.
    Galluzzi F; Stagi S; Salti R; Toni S; Piscitelli E; Simonini G; Falcini F; Chiarelli F
    Eur J Endocrinol; 2005 Dec; 153(6):879-85. PubMed ID: 16322394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Value of Osteoprotegerin for Detecting Coronary Artery Calcification in Type 2 Diabetes Mellitus Patients in Correlation with Extent of Calcification Detected by Multidetector Computed Tomography.
    Ahmed S; Sobh R
    Endocr Metab Immune Disord Drug Targets; 2019; 19(6):845-851. PubMed ID: 30747085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?
    Rozas Moreno P; Reyes García R; García-Martín A; Varsavsky M; García-Salcedo JA; Muñoz-Torres M
    J Endocrinol Invest; 2013 Jan; 36(1):16-20. PubMed ID: 22391059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystatin C as a potential predictor of osteoprotegerin levels in healthy men, a cross-sectional, observational study.
    Kulcsar-Jakab E; Petho Z; Pap Z; Kalina E; Foldesi R; Balogh A; Antal-Szalmas P; Bhattoa HP
    BMC Musculoskelet Disord; 2015 Aug; 16():227. PubMed ID: 26311162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients.
    Rasmussen LM; Tarnow L; Hansen TK; Parving HH; Flyvbjerg A
    Eur J Endocrinol; 2006 Jan; 154(1):75-81. PubMed ID: 16381994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is paraoxonase 1 a marker of cardiovascular risk in youth with type 1 diabetes? (Study about 109 cases)].
    Fekih O; Triki S; Hellara I; Neffati F; Chouchane S; Neji Gueddiche M; Fadhel Najjar M
    Presse Med; 2015 May; 44(5):e185-90. PubMed ID: 25769648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma osteoprotegerin concentrations in type 1 diabetic patients with albuminuria.
    Elsamahy MH; Elhenawy YI; Nawar MM
    J Diabetes Complications; 2015; 29(4):563-7. PubMed ID: 25744546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes.
    Gordin D; Soro-Paavonen A; Thomas MC; Harjutsalo V; Saraheimo M; Bjerre M; Forsblom C; Flyvbjerg A; Groop PH;
    Diabetes Care; 2013 Jul; 36(7):1827-33. PubMed ID: 23801795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy: Results from the Poznań Prospective Study.
    Grzelka A; Naskręt D; Araszkiewicz A; Uruska A; Wegner M; Zozulińska-Ziółkiewicz D
    Adv Clin Exp Med; 2017 Dec; 26(9):1343-1349. PubMed ID: 29442454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.
    Xiang GD; Sun HL; Zhao LS
    Diabetes Res Clin Pract; 2007 May; 76(2):199-206. PubMed ID: 17023086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients.
    Nybo M; Poulsen MK; Grauslund J; Henriksen JE; Rasmussen LM
    Diabet Med; 2010 Mar; 27(3):289-94. PubMed ID: 20536491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.